Unaudited Interim Results to 30 June 2026
Summary by AI BETAClose X
6 August 2026
ProBiotix Health plc
("ProBiotix" or the "Company")
Unaudited Interim Results to 30 June 2026
ProBiotix Health plc (AQSE: PBX), the life sciences business developing probiotics to support cardiometabolic health, announces its unaudited results for the six months to 30 June 2026.
Key Financial Highlights
· Gross revenue +53% to £2.06m (H1 2025: £1.34m)
· Gross profit +66% to £1.245m (H1 2025: £748,000)
· EBITDA profit £151,000* (H1 2025: £112,000 loss)
· Strong cash balance of £1.244m (H1 2025: £1.3m)
*Excluding share-based payments
Operational Highlights
· Five new partnerships established
· Significant growth of existing customer base
· Strong growth in China through Kemin partnership
· Repositioned US strategy for stronger market penetration in 2027
· Recruitment for clinical study to investigate potential impact of LPLDL® in prediabetes and diabetes
Steen Andersen, CEO of ProBiotix commented: "We are pleased with the performance of the business in the first half of the financial year, and the progress we are making. The active customer base has grown by more than 15% during this period, which reflects the growing demand for effective science-backed preventive cardiometabolic supplement products.
We expect further growth in H2 from APAC and the EMEA regions and going into 2027 through the repositioning of a deeper US offering, expanding sales to include third party distribution and a broadened product positioning to offer LPLDL® beyond cholesterol health."
For further information, please contact:
|
ProBiotix Health plc |
|
|
|
investors@probiotixhealth.com |
|
Steen Andersen, Chief Executive Officer Miles Nolan, Investor Relations |
|
|
|
|
|
AlbR Capital Limited Aquis Corporate Adviser and Broker |
Tel: 020 7469 0930 |
|
David Coffman Dan Harris |
|
This announcement contains information which, prior to its disclosure, was considered inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.
Notes to Editors:
ProBiotix Health is a life sciences company that develops probiotic formulations to support cardiometabolic health. Since its formation, ProBiotix has become recognised as a global leader in microbiome modulating probiotics for use in food supplements and nutraceuticals.
The Company has a unique approach; discovering ground breaking probiotics, ensuring their benefits through robust science, and bringing to market effective finished probiotic-based products for human health across the globe.
Chief Executive Officer's overview
The momentum in the business has continued in the first half of 2026, with record revenue growth and a pleasing increase in our gross margin. Moreover, our stated strategy to increase market awareness and boost market penetration, has led to a significant expansion of the customer base.
The Company has continued to expand its global footprint, with the APAC region again proving a particularly strong market. Our partnership with Kemin continues to develop, leading to increasing demand in China.
Revenue for the first six months of 2026 reached a record £2.06m, a 53% increase compared with the same period in 2025. As a result of this increased sales traction, the Group has achieved a swing to an EBITDA profit (excluding share-based payments) for the period of £151,000 (2025: £112,000 loss).
The Board and Management are pleased with the performance achieved in the first half of the year, as it provides further evidence of the success of our strategy.
Strategic Outlook
As a life sciences company with a strategic focus on probiotics and the human microbiome, there remains a significant market opportunity to continue our expansion. ProBiotix operates in the dietary supplement prevention segment, a market which is being driven by the consumer trend of healthy ageing, cardiometabolic health and probiotics.
The strategy continues to target partnerships with scientifically driven dietary supplement suppliers, consumer health and Over the Counter (OTC) companies globally. We continue to provide private label as well as turnkey probiotic dietary supplements to target preventative cardiometabolic health and healthy ageing. The patented LPLDL® continues to be our flagship probiotic strain, developed specifically to support cardiometabolic health.
Results
The Group has delivered a solid trading result during the period, with revenue increasing 53% to £2.06m (2025: £1.34m). Gross profit rose to £1.245m (2025: £748,000), which equated to an increased gross margin of 60.4% (2025: 55%).
Importantly, the Group has achieved a swing to an EBITDA profit (excluding share-based payments) for the period of £151,000 (2025: £112,000 loss). This improvement has been achieved by increased sales volumes, as well as continued operational efficiencies.
The Group ended the period with a cash and cash equivalents of £1.244m, compared to £1.3m at the prior period end. The movement in the bank balance arises from a higher net trade debtor position relative to trade creditors at the current period end compared with the prior period. This is sufficient to deliver our expansion ambitions and leaves the Group fully funded as a result.
Outlook
The active customer base has grown by more than 15% during this period which reflects the growing demand for effective science-backed preventive cardiometabolic supplement products.
We expect further growth in H2 from APAC and the EMEA regions and going into 2027 through the repositioning of a deeper US offering expanding sales to include third party distribution, and a broadened product positioning to offer LPLDL® beyond cholesterol health.
The Board and wider management team remain fully committed to delivering the growth strategy we have articulated. We would like to thank all our shareholders and wider stakeholders for their support, and view the future with confidence.
Consolidated Statement of Comprehensive Income
For the 6 months to 30 June 2026
|
|
|
|
6 months to 30 June 2026 Unaudited |
6 months to 30 June 2025 Unaudited |
Year ended 31 December 2025 Audited |
|
Continuing operations |
|
|
£'000 |
£'000 |
£'000 |
|
|
|
|
|
|
|
|
Revenue |
3 |
|
2,059 |
1,344 |
2,732 |
|
|
|
|
|
|
|
|
Cost of sales |
|
|
(814) |
(596) |
(1,250) |
|
|
|
|
─────── |
─────── |
─────── |
|
Gross Profit |
|
|
1,245 |
748 |
1,482 |
|
|
|
|
|
|
|
|
Share based payments |
|
|
(46) |
(16) |
(753) |
|
Depreciation and amortisation |
|
|
(26) |
(25) |
(54) |
|
Other administrative costs |
|
|
(1,094) |
(860) |
(1,910) |
|
|
|
|
|
|
|
|
|
|
|
─────── |
─────── |
─────── |
|
Total administrative expenses |
|
|
(1,166) |
(901) |
(2,717) |
|
|
|
|
─────── |
─────── |
─────── |
|
Operating profit/(loss) |
|
|
79 |
(153) |
(1,235) |
|
|
|
|
|
|
|
|
Finance income / (costs) |
|
|
- |
- |
- |
|
|
|
|
─────── |
─────── |
─────── |
|
Profit/(Loss) before Income tax |
|
|
79 |
(153) |
(1,235) |
|
|
|
|
|
|
|
|
Income tax |
|
|
7 |
3 |
2 |
|
|
|
|
─────── |
─────── |
─────── |
|
Profit/(Loss) for the period |
|
|
86 |
(150) |
(1,233) |
|
|
|
|
|
|
|
|
Other Comprehensive Income |
|
|
- |
- |
- |
|
|
|
|
─────── |
─────── |
─────── |
|
Total comprehensive income for the period |
|
|
86
|
(150) |
(1,233) |
|
|
|
|
═══════ |
═══════ |
═══════ |
|
|
|
|
|
|
|
|
Total comprehensive income attributable to the owners of the Group |
|
|
86 |
(150)
|
(1,233)
|
|
|
|
|
═══════ |
═══════ |
═══════ |
|
|
|
|
86 |
(150) |
(1,233) |
|
Earnings/(loss) per share |
|
|
|
|
|
|
Basic & Diluted - pence |
4 |
|
0.05p |
(0.09)p |
(0.78)p |
|
|
|
|
═══════ |
═══════ |
═══════ |
Consolidated Statement of Financial Position
As at 30 June 2026
|
|
Notes |
As at 30 June 2026 Unaudited |
As at 30 June 2025 Unaudited |
As at 31 December 2025 Audited |
|
ASSETS |
|
£'000 |
£'000 |
£'000 |
|
Non-current assets |
|
|
|
|
|
Intangibles |
|
161 |
211 |
186 |
|
Property plant and equipment |
|
6 |
7 |
5 |
|
|
|
─────── |
─────── |
─────── |
|
|
|
167 |
218 |
191 |
|
|
|
─────── |
─────── |
─────── |
|
CURRENT ASSETS |
|
|
|
|
|
Inventories |
|
- |
17 |
- |
|
Trade and other receivables |
|
560 |
846 |
351 |
|
Cash and cash equivalents |
|
1,244 |
1,299 |
1,266 |
|
|
|
─────── |
─────── |
─────── |
|
|
|
1,804 |
2,162 |
1,617 |
|
|
|
─────── |
─────── |
─────── |
|
TOTAL ASSETS |
|
1,971 |
2,380 |
1,808 |
|
|
|
═══════ |
═══════ |
═══════ |
|
EQUITY |
|
|
|
|
|
Shareholders' Equity |
|
|
|
|
|
Called up share capital |
5 |
79 |
79 |
79 |
|
Group reorganisation reserve |
|
(945) |
(945) |
(945) |
|
Share premium |
|
4,534 |
4,534 |
4,534 |
|
Share based payment reserve |
|
840 |
57 |
794 |
|
Retained Earnings |
|
(2,933) |
(1,936) |
(3,019) |
|
|
|
|
|
|
|
|
|
─────── |
─────── |
─────── |
|
Total Equity |
|
1,575 |
1,789 |
1,443 |
|
|
|
─────── |
─────── |
─────── |
|
LIABILITIES |
|
|
|
|
|
Current liabilities |
|
|
|
|
|
Trade and other payables |
|
356 |
538 |
318 |
|
|
|
─────── |
─────── |
─────── |
|
|
|
356 |
538 |
318 |
|
|
|
─────── |
─────── |
─────── |
|
Non - current liabilities |
|
|
|
|
|
Deferred tax liability |
|
40 |
53 |
47 |
|
|
|
─────── |
─────── |
─────── |
|
|
|
40 |
53 |
47 |
|
|
|
─────── |
─────── |
─────── |
|
TOTAL LIABILITIES |
|
396 |
591 |
365 |
|
|
|
─────── |
─────── |
─────── |
|
|
|
|
|
|
|
TOTAL EQUITY AND LIABILITIES |
|
1,971 |
2,380 |
1,808 |
|
|
|
|
|
|
|
|
|
═══════ |
═══════ |
═══════ |
Consolidated Statement of Changes in Equity
For six months to 30 June 2026
|
|
Called up Share Capital |
Share premium |
Group Reorganisation reserve |
Share-based Payment reserve |
Retained Earnings |
Total Equity |
|
|
£'000 |
£'000 |
£'000 |
£'000 |
£'000 |
£'000 |
|
|
────── |
─────── |
─────── |
─────── |
────── |
─────── |
|
Balance at 31 December 2024 |
79 |
4,534 |
(945) |
41 |
(1,786) |
1,923 |
|
|
|
|
|
|
|
|
|
Loss for the period |
- |
- |
- |
- |
(150) |
(150) |
|
|
|
|
|
|
|
|
|
Share based payments |
- |
- |
- |
16 |
- |
16 |
|
|
────── |
─────── |
─────── |
─────── |
────── |
─────── |
|
Balance at 30 June 2025 |
79 |
4,534 |
(945) |
57 |
(1,936) |
1,789 |
|
|
|
|
|
|
|
|
|
Loss for the period |
- |
- |
- |
- |
(1,083) |
(1,083) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Share based payments |
- |
- |
- |
737 |
- |
737 |
|
|
|
|
|
|
|
|
|
|
────── |
─────── |
─────── |
─────── |
────── |
─────── |
|
Balance at 31 December 2025 |
79 |
4,534 |
(945) |
794 |
(3,019) |
1,443 |
|
|
|
|
|
|
|
|
|
Profit for the period |
- |
- |
- |
- |
86 |
86 |
|
|
|
|
|
|
|
|
|
Share based payments |
- |
- |
- |
46 |
- |
46 |
|
|
|
|
|
|
|
|
|
|
────── |
─────── |
─────── |
─────── |
────── |
─────── |
|
Balance at 30 June 2026 |
79 |
4,534 |
(945) |
840 |
(2,933) |
1,575 |
|
|
────── |
─────── |
─────── |
─────── |
────── |
─────── |
Consolidated Statement of Cash Flows
For the six months to 30 June 2026
|
|
Notes |
6 months to 30 June 2026 Unaudited |
Period to 30 June 2025 Unaudited |
Year ended 31 December 2025 Audited |
|
|
|
£'000 |
£'000 |
£'000 |
|
Reconciliation of loss before income tax to cash outflow from operations |
|
|
|
|
|
Operating profit/(loss) |
|
79 |
(153) |
(1,235) |
|
Decrease/ (Increase) in inventories |
|
- |
14 |
31 |
|
(Increase)/decrease in trade and other receivables |
|
(208) |
(589) |
(94) |
|
(Decrease)/increase in trade and other payables |
|
38 |
343 |
123 |
|
Share based payments |
|
46 |
16 |
753 |
|
Depreciation and amortisation |
|
26 |
25 |
54 |
|
Net Fx Difference |
|
|
(3) |
- |
|
|
|
────── |
────── |
────── |
|
Net cash outflow from operations |
|
(19) |
(347) |
(368) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Tax received |
|
- |
- |
- |
|
|
|
────── |
────── |
────── |
|
Net cash (outflow)/inflow from operating activities |
|
(19) |
(347) |
(368) |
|
|
|
|
|
|
|
Cash flows from investing activities |
|
|
|
|
|
|
|
|
|
|
|
Purchase of intangible assets |
|
(3) |
- |
(12) |
|
|
|
────── |
────── |
────── |
|
Net cash (outflow)/inflow from investing activities |
|
(3) |
- |
(12) |
|
|
|
────── |
────── |
────── |
|
Cash flows from financing activities |
|
|
|
|
|
Share issue net of costs |
|
- |
- |
- |
|
|
|
────── |
────── |
────── |
|
Net cash inflow from financing activities |
|
- |
- |
- |
|
|
|
────── |
────── |
────── |
|
|
|
|
|
|
|
Increase/(decrease) in cash and equivalents |
|
(22) |
(347) |
(380) |
|
|
|
|
|
|
|
Cash and cash equivalents at beginning of period |
|
1,266 |
1,646 |
1,646 |
|
|
|
────── |
────── |
────── |
|
Cash and cash equivalents at end of period |
|
1,244 |
1,299 |
1,266 |
|
|
|
══════ |
══════ |
══════ |
Notes to the results
For the six months to 30 June 2026
1. General Information
ProBiotix Health plc is a company incorporated and domiciled in England and Wales. The Company's offices are in Wakefield. The Company is listed on the Aquis Growth Market (ticker: PBX).
The financial information set out in this report does not constitute statutory accounts as defined in Section 434 of the Companies Act 2006. The Group's statutory financial statements for the period ended 31 December 2025 were prepared under UK - adopted International Financial Reporting Standards ("IFRS").
Copies of the annual statutory accounts and the Half Yearly report can be found on the Company's website https://probiotixhealth-ir.com/financials/latest-results
2. Basis of preparation and significant accounting policies
This report has been prepared using the historical cost convention, on a going concern basis and in accordance with UK - adopted International Financial Reporting Standards ("IFRS").
The preparation of financial statements in conformity with IFRS requires the use of certain critical accounting estimates. It also requires management to exercise its judgement in the process of applying the accounting policies and making any estimates. Changes in assumptions may have a significant impact on the financial statements in the period the assumptions changed. The Board of Directors believe that the underlying assumptions are appropriate and that the financial statements are fairly presented. The Board of Directors believes that there are no areas involving a higher degree of judgement or complexity, or areas where assumptions and estimates are significant to the financial statements, and therefore, these financial statements have limited disclosures.
3. Segmental Reporting
In the opinion of the directors, the Group has one class of business, in four geographical areas, being that of identifying and developing microbial strains, compounds and formulations for use in the nutraceutical industry. The Group sells into three highly interconnected markets, all costs assets and liabilities are derived from locations in the UK and Denmark.
Revenue analysed by geographical market
|
|
6 months 30 June 2026 |
6 months 30 June 2025 |
Year to 31 December 2025 |
|
|
£'000 |
£'000 |
£'000 |
|
UK |
- |
34 |
61 |
|
US |
1,048 |
760 |
1,810 |
|
China |
276 |
51 |
- |
|
ROW |
735 |
499 |
861 |
|
|
────── |
────── |
────── |
|
|
2,059 |
1,344 |
2,732 |
|
|
══════ |
══════ |
══════ |
During the reporting period one customer represented £1.014m, 49.2% (2025: £689k, 51.2%) of Group revenues.
4. Earnings per Share
Basic earnings per share is calculated by dividing the earnings attributable shareholders by the weighted average number of ordinary shares outstanding during the period.
Reconciliations are set out below:
|
|
6 Months to 30 June 2026 Unaudited |
6 Months to 30 June 2025 Unaudited |
Year to 31 December 2025 Audited |
|
|
£ |
£ |
£ |
|
Basic & Diluted |
|
|
|
|
|
|
|
|
|
Earnings attributable to ordinary shareholders |
86,000 |
(150,000) |
(1,233,000) |
|
|
|
|
|
|
Weighted average number of shares |
158,166,666 |
158,166,666 |
158,166,666 |
|
|
|
|
|
|
Earnings /(Loss) per-share - pence |
0.05p |
(0.09)p |
(0.78)p |
|
|
═════ |
═════ |
═════ |
|
|
|
|
|
As at 30 June 2026 there were 14,750,000 (2025: 14,750,000) outstanding share options. These are non-dilutive due to the strike price being above the share price at the period end.
5. Share Capital
Issued share capital comprises:
|
Shares in issue |
|
|
|
|
|
Opening balance 1 January 2025 and 30 June 2025 |
158,166,666 |
|
|
|
|
|
────── |
|
Closing balance at 31 December 2025 and 30 June 2026 |
158,166,666 |
|
|
══════ |
|
Share capital |
£'000 |
|
|
|
|
Opening balance 1 January 2025 and 30 June 2025 |
79 |
|
|
|
|
|
────── |
|
Closing balance at 31 December 2025 and 30 June 2026 |
79 |
|
|
══════ |
6. Post balance sheet events
There are no post balance sheet events.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 9 hours ago Johnson Matthey
- 10 hours ago Galliford Try
- 10 hours ago Galliford Try
- 10 hours ago Centrica
- 11 hours ago Smith & Nephew